High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma

National Medical Journal of India

Volumn 16, Issue 1, 2003, Pages 16-21

  Kumar, Lalit ^a   Raju, G M K ^a   Ganessan, K ^a   Shawgi, S ^a   Menon, H ^a   Wadhwa, J ^a   Sharma, A ^a   Singh, Rajveer ^a   Kochupillai, V ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HYDROCORTISONE; ITRACONAZOLE; MELPHALAN; PHENIRAMINE MALEATE; PREDNISOLONE; TUBERCULOSTATIC AGENT; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; ASPERGILLUS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACTERIAL INFECTION; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANDIDA; CELL COUNT; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDIA; KAPLAN MEIER METHOD; KIDNEY DISEASE; LEUKAPHERESIS; LEUKOCYTE COUNT; LIVER DISEASE; MALE; MONONUCLEAR CELL; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NAUSEA AND VOMITING; PATIENT CARE; PROBABILITY; SALVAGE THERAPY; SYMPTOM; THROMBOCYTE TRANSFUSION; TIME; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0037268803     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-64.
2. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 1992;10:334-42.
3. Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2:882-5.
4. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86-9.
5. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 1983;2:822-4.
6. Selby PJ, Mac Elwain TJ, Nandi AC, Perrn TJ, Powles RL, Tillyer CR, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987;66:55-62.
7. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, et al. Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993;82:2324-8.
8. Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Blood 1995;85:3077-85.
9. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francaise du Myelome. N Engl J Med 1996;335:91-7.
10. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997;20:435-43.
11. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-93.
12. Schiller G, Vesico R, Freytes C, Spitzen G, Lee M, Wu CH, et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant 1998;21:141-5.
13. Lokhurst HM, Sonneveld P, Verdonck LF. Intensive treatment for multiple myeloma. Where do we stand? Br J Haematol 1999;106:18-27.
14. Fermand JP, Ravaud P, Katsahian S, Divine M, Leblond V, Belauger C, et al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: Results of a randomized trial in 190 patients 55-85 years of age. Blood 1999;94(Suppl 1):396a(abstract).
15. Palumbo A, Triolo S, Argentino C, Bringham S, Dominietto A, Rus C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248-53.
16. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
17. Joshua DE, Penny R, Mattews JP, Laidlaw CR, Gibson J, Bradstock K, et al. Australian Leukemia Study Group Myeloma II: A randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haematol 1997;97:38-45.
18. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman PT, Apperley J, Remesk, et al. 5489 autotransplants in multiple myeloma: A registry from the EBMT. Blood 1999;94(Suppl 1):714a(abstract).
19. Blade J, Esteve J, Rives S, Martinez C, Rovira M, Urbano-Ispizua A, et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000;26:845-9.
20. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008-10.
21. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
22. Raju GMK, Kochupillai V, Kumar L. Storage of haematopoietic stem cells for autologous bone marrow transplantation. Natl Med J India 1995;8:216-21.
23. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-8.
24. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose chemotherapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
25. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood 1993;82:2975-84.
26. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63.
27. Reece DE. Evidence based management of Hodgkin's disease: The role of autologous stem cell transplantation. Cancer Control 2000;7:266-75.
28. Philip T, Guglielmi C, Hagenbeek A, Somers A, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
29. Frei E III, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
30. Harousseau JL. High dose chemotherapy in multiple myeloma. In: Broudy VC, Abkowitz JL, Vose JM (eds). Hematology 2001, American Society of Hematology Educational Program Book. Seattle:American Society of Hematology, 2001:165-9.
31. International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry (IBMTR/ABMTR) Newsletter. 2000;7:3-10.
32. Kumar L, Gulati SC. Peripheral blood stem cell transplantation. Lancet 1997;S9:346.
33. Stiff P. Mucositis associated with stem cell transplantation: Current status and innovative approaches to management. Bone Marrow Transplant 2001;27 (Suppl 2):S3-S11.
34. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, Alegre A, Blade J, Martinez R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000;1:28-36.
35. Sirohi B, Powles R. International myeloma grand round. Lancet Oncol 2001;2:571-9.
36. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
37. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-71.
38. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Haematol 1998;102:495-502
39. Blade J, Esteve J. View point on the impact of interferon in the treatment of multiple myeloma: Benefit for a small proportion of patients? Med Oncol 2000;17:77-84.